Diffuse astrocytomas, also referred to as low-grade infiltrative astrocytomas, are designated as WHO II tumours of the brain. The term diffuse infiltrating means there is no identifiable border between the tumour and the normal brain tissue even though the borders may appear well marginated on imaging.
In the 2016 update to the WHO classification of CNS tumours, diffuse astrocytoma is synonymous with the previously described subtype of fibrillary astrocytoma. Gemistocytic astrocytoma remains a distinct subtype, whereas protoplasmic astrocytomas are no longer recognised as a separate entity 13.
IDH mutation status is critically important, and astrocytomas are now defined as IDH mutant or IDH wild-type 13.
This article will focus on the general features of diffuse astrocytomas (the most common type). Each subtype mentioned above is discussed in more detail separately.
The term diffuse astrocytoma should not be used for a specific, non-infiltrative tumours of astrocyte-lineage such as pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma and pilocytic astrocytoma, as these have different prognoses, treatment and imaging features.
Diffuse astrocytomas are divided into two molecular groups according to IDH status:
- IDH mutant
- IDH wild-type
If IDH status is unavailable they are known as diffuse astrocytoma NOS (not otherwise specified).
Importantly, if IDH is shown to be mutated then 1p19q status must be determined and shown to be not co-deleted (otherwise even with astrocytic histology, an IDH mutated, 1p19q co-deleted tumours is now classified as an oligodendroglioma).
It is also worth noting, that is it likely that the entity diffuse astrocytoma IDH wild-type will eventually vanish, as it is felt that most of these tumours harbour a variety of other distinctive genetic profiles and likely represent a collection of other tumours with astrocytic histological differentiation 13.
Diffuse low-grade gliomas of the cerebral hemispheres are typically diagnosed in young adults between 20-45 years old (mean 35 years of age). There is, in fact, a biphasic distribution, with one peak in childhood (6-12 years) and the other peak in early adulthood (26-46 years)1. Childhood gliomas are mostly diffuse brainstem gliomas, which are discussed separately.
There is a slight male predilection is described (M:F ~1.5) 1.
The most common presenting feature (~40% of cases) is a seizure. This is particularly the case in adults. Headaches are often also present. Depending on the size of the lesion and its location other features may be present, such as hydrocephalus and focal neurological dysfunction including personality change.
Diffuse low-grade astrocytomas are predominantly composed of a microcystic tumour matrix within which are embedded fibrillary neoplastic astrocytes with mild nuclear atypia and a low cellular density. Often microcystic spaces containing mucinous fluid are present, a typical finding in fibrillary astrocytomas, but even more characteristic and pronounced in protoplasmic astrocytomas.
The occasional occurrence of gemistocytes in a diffuse astrocytoma does not justify the diagnosis of gemistocytic astrocytoma. Gemistocytic astrocytomas tend to progress more rapidly to anaplastic astrocytoma and secondary glioblastoma than fibrillary astrocytoma although they share the WHO grade II.
Mitoses, microvascular proliferation and necrosis are absent (if present they suggest a high-grade tumour). Like all tumours derived from astrocytes, fibrillary astrocytomas stain with glial fibrillary acidic protein (gFAP) 2-3.
It is well recognised that pathological classification has a high interobserver variation and thus imperfectly predicts clinical outcomes 11. Recent studies have shown that the genetic status of these tumours are more reflective of their subtypes than the histologic grading (please refer on isocitrate dehydrogenase (IDH) for a broad discussion on this topic) 11.
MRI is the modality of choice for characterising these lesions, and in the case of smaller tumours, they may be subtle and difficult to see on CT, especially as they tend not to enhance.
Typically low-grade infiltrating astrocytomas appear as isodense or hypodense regions of positive mass effect, often without any enhancement (in fact presence of enhancement would suggest higher grade tumours), although particularly gemistocytic astrocytomas can demonstrate wispy enhancement.
Calcification is not common (10-20% of cases)1 and may be related to oligodendroglial components (i.e oligoastrocytoma).
Cystic or fluid attenuation components are also encountered, particularly in gemistocytic and protoplasmic varieties.
Reported signal characteristics include:
- isointense to hypointense compared to white matter
- usually confined to the white matters and causes expansion of the adjacent cortex
- mass-like hyperintense signals
- always follow the white matter distribution and cause expansion of the surrounding cortex
- cortex can also, be involved in late cases in comparison to the oligodendroglioma, which is a cortical-based tumour from the start
- the "microcystic changes" along the lines of spread of the infiltrative astrocytoma is a unique behaviour for the infiltrative astrocytoma, however, it is only appreciated in a few number of cases
- high T2 signal is NOT related to cellularity or cellular atypia, but rather oedema, demyelination and other degenerative change 10
- typically has facilitated diffusion, with lower ADC values suggesting higher grade
T1 C+ (Gd)
- no enhancement is often the rule but small ill-defined areas of enhancement are not rare; however, when enhancement is seen it should be considered as a warning sign for progression to a higher grade
- MR spectroscopy
- MR perfusion: no elevation of rCBV
- has FDG uptake similar to the normal white matter
- FDG,18-F-Choline and 11C-choline PET useful for biopsy (most hypermetabolic area)
Treatment and prognosis
Treatment depends on clinical presentation, the size of the tumour and location. Historically these tumours were managed as follows:
- biopsy to confirm the diagnosis and observe
- surgical resection if feasible
- usually radiotherapy at the time of recurrence or progression
There is an increasing body of evidence that suggests that chemotherapy+/- radiotherapy, usually reserved for tumours that progressed to higher grades, may be of benefit in lower grade tumours also.
Possible imaging differential considerations include:
- 1. Tonn J, Westphal M. Neuro-oncology of CNS tumors. Springer Verlag. (2006) ISBN:3540258337. Read it at Google Books - Find it at Amazon
- 2. David G. McLone. Pediatric Neurosurgery. Saunders. (2001) ISBN:072168209X. Read it at Google Books - Find it at Amazon
- 3. Lind-LandströM T, Habberstad AH, SundstrøM S et-al. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012;5 (2): 152-8. Free text at pubmed - Pubmed citation
- 4.Law M, Oh S, Johnson G et-al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery. 2006;58 (6): 1099-107. doi:10.1227/01.NEU.0000215944.81730.18 - Pubmed citation
- 5.Law M, Oh S, Babb JS et-al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology. 2006;238 (2): 658-67. doi:10.1148/radiol.2382042180 - Pubmed citation
- 6. Bertholdo D, Watcharakorn A, Castillo M.Brain Proton Magnetic Resonance Spectroscopy.www.ajnr.org/site/fellows/files/MRS-chapter-Castillo.pdf
- 7. Louis DN, Ohgaki H, Wiestler OD et-al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114 (2): 97-109. Acta Neuropathol. (full text) - doi:10.1007/s00401-007-0243-4 - Free text at pubmed - Pubmed citation
- 8. Weissleder R, Wittenberg J, Harisinghani MMGH et-al. Primer of Diagnostic Imaging. Mosby. (2011) ISBN:0323065384. Read it at Google Books - Find it at Amazon
- 9. Fisher PG, Breiter SN, Carson BS et-al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000;89 (7): 1569-76. Pubmed citation
- 10. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34 (6): 463-9. Pubmed citation
- 11. Brat DJ, Verhaak RG et-al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 2015;372 (26): 2481-98. doi:10.1056/NEJMoa1402121 - Free text at pubmed - Pubmed citation
- 12.Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol. 2000;21 (9): 1645-9. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 13. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK "WHO Classification of Tumours of the Central Nervous System. 4th Edition Revised" ISBN: 9789283244929
- WHO classification of CNS tumours
- WHO grading of CNS tumours
- VASARI MRI feature set
- diffuse astrocytoma grading
- grade I:
- grade II:
- grade III
- grade IV:
- glioblastoma vs cerebral metastasis
- radiation-induced gliomas
- gliomatosis cerebri (growth pattern)
- specific locations
- treatment response
- Stupp protocol
- glioma treatment response assessment in clinical trials
- multicentric glioblastoma
- multifocal glioblastoma
- prognostic genetic markers